Cargando…

Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders

Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from Dracocep...

Descripción completa

Detalles Bibliográficos
Autores principales: Khattulanuar, Farrah Syazana, Sekar, Mahendran, Fuloria, Shivkanya, Gan, Siew Hua, Rani, Nur Najihah Izzati Mat, Ravi, Subban, Chidambaram, Kumarappan, Begum, M. Yasmin, Azad, Abul Kalam, Jeyabalan, Srikanth, Dhiravidamani, Arulmozhi, Thangavelu, Lakshmi, Lum, Pei Teng, Subramaniyan, Vetriselvan, Wu, Yuan Seng, Sathasivam, Kathiresan V., Fuloria, Neeraj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838974/
https://www.ncbi.nlm.nih.gov/pubmed/35163934
http://dx.doi.org/10.3390/molecules27030673
_version_ 1784650255020589056
author Khattulanuar, Farrah Syazana
Sekar, Mahendran
Fuloria, Shivkanya
Gan, Siew Hua
Rani, Nur Najihah Izzati Mat
Ravi, Subban
Chidambaram, Kumarappan
Begum, M. Yasmin
Azad, Abul Kalam
Jeyabalan, Srikanth
Dhiravidamani, Arulmozhi
Thangavelu, Lakshmi
Lum, Pei Teng
Subramaniyan, Vetriselvan
Wu, Yuan Seng
Sathasivam, Kathiresan V.
Fuloria, Neeraj Kumar
author_facet Khattulanuar, Farrah Syazana
Sekar, Mahendran
Fuloria, Shivkanya
Gan, Siew Hua
Rani, Nur Najihah Izzati Mat
Ravi, Subban
Chidambaram, Kumarappan
Begum, M. Yasmin
Azad, Abul Kalam
Jeyabalan, Srikanth
Dhiravidamani, Arulmozhi
Thangavelu, Lakshmi
Lum, Pei Teng
Subramaniyan, Vetriselvan
Wu, Yuan Seng
Sathasivam, Kathiresan V.
Fuloria, Neeraj Kumar
author_sort Khattulanuar, Farrah Syazana
collection PubMed
description Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from Dracocephalum moldavica. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin’s preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin’s cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives.
format Online
Article
Text
id pubmed-8838974
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88389742022-02-13 Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders Khattulanuar, Farrah Syazana Sekar, Mahendran Fuloria, Shivkanya Gan, Siew Hua Rani, Nur Najihah Izzati Mat Ravi, Subban Chidambaram, Kumarappan Begum, M. Yasmin Azad, Abul Kalam Jeyabalan, Srikanth Dhiravidamani, Arulmozhi Thangavelu, Lakshmi Lum, Pei Teng Subramaniyan, Vetriselvan Wu, Yuan Seng Sathasivam, Kathiresan V. Fuloria, Neeraj Kumar Molecules Review Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from Dracocephalum moldavica. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin’s preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin’s cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives. MDPI 2022-01-20 /pmc/articles/PMC8838974/ /pubmed/35163934 http://dx.doi.org/10.3390/molecules27030673 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Khattulanuar, Farrah Syazana
Sekar, Mahendran
Fuloria, Shivkanya
Gan, Siew Hua
Rani, Nur Najihah Izzati Mat
Ravi, Subban
Chidambaram, Kumarappan
Begum, M. Yasmin
Azad, Abul Kalam
Jeyabalan, Srikanth
Dhiravidamani, Arulmozhi
Thangavelu, Lakshmi
Lum, Pei Teng
Subramaniyan, Vetriselvan
Wu, Yuan Seng
Sathasivam, Kathiresan V.
Fuloria, Neeraj Kumar
Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
title Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
title_full Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
title_fullStr Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
title_full_unstemmed Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
title_short Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
title_sort tilianin: a potential natural lead molecule for new drug design and development for the treatment of cardiovascular disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838974/
https://www.ncbi.nlm.nih.gov/pubmed/35163934
http://dx.doi.org/10.3390/molecules27030673
work_keys_str_mv AT khattulanuarfarrahsyazana tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT sekarmahendran tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT fuloriashivkanya tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT gansiewhua tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT raninurnajihahizzatimat tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT ravisubban tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT chidambaramkumarappan tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT begummyasmin tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT azadabulkalam tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT jeyabalansrikanth tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT dhiravidamaniarulmozhi tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT thangavelulakshmi tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT lumpeiteng tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT subramaniyanvetriselvan tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT wuyuanseng tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT sathasivamkathiresanv tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders
AT fulorianeerajkumar tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders